ARTICLE | Product Development
Pazdur’s PD-1 plea
FDA oncology chief calls on companies to cut the redundancy and collaborate in the checkpoint stampede
December 17, 2021 12:42 AM UTC
FDA’s Richard Pazdur is making a plea to the biopharma industry to stop running in parallel lanes on PD-1 and work together.
With 15 anti-PD-1 or anti-PD-L1 mAbs approved globally, and at least 38 in clinical development being tested in more than 2,000 clinical trials, the field has drawn criticism both inside and outside the industry...